코로나-19 환자의 후유증 한약 치료에 대한 고찰
Review on Herbal Medicine Treatment for Late Complications of COVID-19 Patients
6
조회
0
다운로드
17
인용
0
참고문헌
키워드
초록
Objective: The purpose of this study was to collect and evaluate evidence of herbal medicine treatments for the residual effects of COVID-19. Methods: Nine electronic databases, namely PubMed, Science Direct, CINAHL, CNKI, Wanfang, J-STAGE, CiNii, OASIS, and Science ON, were searched with the following keywords: ‘COVID-19’; ‘sequelae’; ‘Convalescence’ for ‘P (Population)’ and ‘Medicine, Chinese Traditional’; ‘Korean medicine’; ‘Herbal medicine’ for ‘I (Intervention)’. For the selected studies, various clinical data were extracted including patient symptoms, pattern identification, herbal medicines prescribed, and treatment results. Results: A total of nine clinical studies were identified (two case control trials; one case series; and six case reports). Various residual symptoms had been detected in the recovery stage of COVID-19 with the most commonly used pattern identifications being deficiency in both lung and spleen and in both qi and yin. Any herbal medicine prescriptions were written using these patterns. We found several reports of the positive effect of herbal medicines in that it improved symptoms, lung function, and lung inflammation. No adverse events were reported. Conclusions: The results indicate that treatment with herbal medicines has a possible therapeutic effect on the residual symptoms of COVID-19. Large-scale studies are necessary to confirm the effectiveness of these approaches.
Abstract
Objective: The purpose of this study was to collect and evaluate evidence of herbal medicine treatments for the residual effects of COVID-19. Methods: Nine electronic databases, namely PubMed, Science Direct, CINAHL, CNKI, Wanfang, J-STAGE, CiNii, OASIS, and Science ON, were searched with the following keywords: ‘COVID-19’; ‘sequelae’; ‘Convalescence’ for ‘P (Population)’ and ‘Medicine, Chinese Traditional’; ‘Korean medicine’; ‘Herbal medicine’ for ‘I (Intervention)’. For the selected studies, various clinical data were extracted including patient symptoms, pattern identification, herbal medicines prescribed, and treatment results. Results: A total of nine clinical studies were identified (two case control trials; one case series; and six case reports). Various residual symptoms had been detected in the recovery stage of COVID-19 with the most commonly used pattern identifications being deficiency in both lung and spleen and in both qi and yin. Any herbal medicine prescriptions were written using these patterns. We found several reports of the positive effect of herbal medicines in that it improved symptoms, lung function, and lung inflammation. No adverse events were reported. Conclusions: The results indicate that treatment with herbal medicines has a possible therapeutic effect on the residual symptoms of COVID-19. Large-scale studies are necessary to confirm the effectiveness of these approaches.
참고문헌 (24)
- Angelo C, "Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19", JAMA, 324(6), pp.603~605 (2020)[DOI]
- Jang SB, "Telemedicine and the use of Korean medicine for patients with COVID-19 in South Korea:observational study", JMIR Public Health Surveil, 7(1), pp.e20236~ (2021)[DOI]
- Li L, "Effects of Chinese medicine on symptoms, syndrome evolution, and lung inflammation absorption in COVID-19 convalescent patients during 84-day follow-up after hospital discharge:a prospective cohort and nested case-control study", Chin J Integr Med, pp.1~7 (2021)[DOI]
- Shi S, "Clinical studies of comprehensive TCM treatment to 30 cases of Qi Yin deficiency type of COVID-19 in its recovery period", Jiangsu J TCM, 53(1), pp.25~28 (2021)[DOI]
- Li Y, "Clinical characteristics of 86 cases COVID-19 convalescent patients", J Liaoning Univ TCM, 22(9), pp.122~125 (2020)[DOI]
- Jia X, "Traditional Chinese medicine treatment for COVID-19 in recovery stage", Shandong J TCM, 39(9), pp.897~902 (2020)[DOI]
- Xiong F, "Feasibility analysis of Chinese medicine for activate blood and resolve stasis on the recovery stage treatment of COVID-19", Research of Integrated Traditional Chinese and Western Medicine, 12(4), pp.272~275 (2020)[DOI]
- Cong X, "Medication thinking and method of pulmonary fibrosis treatment in recovery stage of COVID-19", Acta Chinese Medicine, 35(267), pp.1583~1586 (2020)[DOI]
- Huang L, "Traditional Chinese medicine diagnosis and treatment protocol for COVID-19 in recovery period and the case analysis", Fujian J TCM, 51(4), pp.4~7 (2020)[DOI]
- Zhao W, "Experience on the traditional Chinese medicine treatment of mild and ordinary type of COVID-19 in middle and recovery period", Shanxi J TCM, 36(4), pp.36~37 (2020)
- Wen L, "Application of Qingzao Yangrong decoction to convalescent patients with COVID-19", Pharmacology and Clinics of Chinese Materia Medica, 36(2), pp.61~63 (2020)[DOI]
- Huang C, "6-month consequences of COVID-19 in patients discharged from hospital a cohort study", Lancet, 397(10270), pp.220~232 (2021)[DOI]
- 정선형, "코로나-19 무증상 감염 환자의 한약 치료 방안에 대한 고찰", 대한한의학회지, 42(1), pp.99~109 (2021), 대한한의학회[DOI]
- Tenforde MW, "Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020", MMWR Morb Mortal Wkly Rep, 69(30), pp.993~998 (2020)[DOI]
- Laura P, "SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids", Cell Stem Cell, 27(6), pp.951~961 (2020)[DOI]
- Zsuzsanna V, "Endothelial cell infection and endotheliitis in COVID-19", Lancet, 295(10234), pp.1417~1418 (2020)[DOI]
- Rapkiewicz AV, "Megakaryocytes and platelet-fibrin thrombi characterize multi- organ thrombosis at autopsy in COVID-19:A case series", E Clinical Medicine, 24, pp.100434~ (2020)[DOI]
- Tripathi MK, "Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor", J Biomol Struct Dyn, pp.1~14 (2020)[DOI]
- "Platycodin D prevents both Iysosome- and TMPRSS2-driven SARS-CoV-2 infection in vitro by hindering membrane fusion" (2020)[URL]
- Huang J, "Current Prevention of COVID-19:Natural Products and Herbal Medicine", Front Pharmacol, 11, pp.588508~ (2020)[DOI]
- Hui DS, "Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors", Thorax, 60(5), pp.401~409 (2005)[DOI]
- 장인수, "중증급성호흡기증후군(SARS) 치료에 사용된 한약 처방에 대한 고찰 - WHO 보고서(2004)에 사용된 처방을 중심으로", 대한한방내과학회지, 30(3), pp.571~581 (2009), 대한한방내과학회
- National health commission, "Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)", Chinese Medical Journal (2020)
- Arita R, "Kakkonto, shosaikoto, Platycodon grandiflorum root, and gypsum (a Japanese original combination drug known as saikatsugekito):Pharmacological review of its activity against viral infections and respiratory inflammatory conditions and a discussion of its applications to COVID-19", Traditional &Kampo Medicine, 7(3), pp.115~127 (2020)[DOI]